David Amsellem
Stock Analyst at Piper Sandler
(4.45)
# 236
Out of 4,829 analysts
145
Total ratings
57.39%
Success rate
14.82%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COLL Collegium Pharmaceutical | Reiterates: Neutral | $36 → $37 | $28.89 | +28.07% | 8 | May 9, 2025 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Overweight | $176 → $147 | $97.78 | +50.34% | 14 | May 7, 2025 | |
| NBIX Neurocrine Biosciences | Reiterates: Overweight | $160 → $154 | $115.71 | +33.09% | 10 | May 6, 2025 | |
| BMY Bristol-Myers Squibb Company | Initiates: Overweight | $65 | $46.45 | +39.94% | 1 | Apr 22, 2025 | |
| CORT Corcept Therapeutics | Maintains: Overweight | $128 → $131 | $70.23 | +86.53% | 7 | Apr 3, 2025 | |
| AMPH Amphastar Pharmaceuticals | Maintains: Neutral | $36 → $32 | $24.18 | +32.34% | 8 | Mar 21, 2025 | |
| OPTN OptiNose | Downgrades: Neutral | $15 → $9 | $9.39 | -4.15% | 3 | Mar 21, 2025 | |
| XERS Xeris Biopharma Holdings | Reiterates: Neutral | $3 → $4 | $5.01 | -20.16% | 5 | Mar 7, 2025 | |
| INDV Indivior | Maintains: Overweight | $16 → $13 | $11.08 | +17.33% | 5 | Mar 6, 2025 | |
| VTRS Viatris | Reiterates: Neutral | $14 → $10 | $8.77 | +14.03% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $310 → $329 | $265.86 | +23.75% | 2 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $30 | $16.93 | +77.20% | 10 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $13 | $9.39 | +38.45% | 5 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $9 | $6.57 | +36.99% | 1 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $11 | $7.41 | +48.45% | 4 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $38 → $37 | $30.13 | +22.80% | 7 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $68 | $66.30 | +2.56% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $41 → $36 | $31.70 | +13.56% | 15 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $9 → $3 | $4.59 | -34.64% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 | $25.12 | +67.20% | 10 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $24 | $8.71 | +175.55% | 5 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $10 | $2.79 | +258.42% | 1 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $0.71 | +2,861.08% | 3 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $113 | $107.76 | +4.86% | 3 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $42 | $34.06 | +23.33% | 3 | Oct 16, 2023 |
Collegium Pharmaceutical
May 9, 2025
Reiterates: Neutral
Price Target: $36 → $37
Current: $28.89
Upside: +28.07%
Jazz Pharmaceuticals
May 7, 2025
Reiterates: Overweight
Price Target: $176 → $147
Current: $97.78
Upside: +50.34%
Neurocrine Biosciences
May 6, 2025
Reiterates: Overweight
Price Target: $160 → $154
Current: $115.71
Upside: +33.09%
Bristol-Myers Squibb Company
Apr 22, 2025
Initiates: Overweight
Price Target: $65
Current: $46.45
Upside: +39.94%
Corcept Therapeutics
Apr 3, 2025
Maintains: Overweight
Price Target: $128 → $131
Current: $70.23
Upside: +86.53%
Amphastar Pharmaceuticals
Mar 21, 2025
Maintains: Neutral
Price Target: $36 → $32
Current: $24.18
Upside: +32.34%
OptiNose
Mar 21, 2025
Downgrades: Neutral
Price Target: $15 → $9
Current: $9.39
Upside: -4.15%
Xeris Biopharma Holdings
Mar 7, 2025
Reiterates: Neutral
Price Target: $3 → $4
Current: $5.01
Upside: -20.16%
Indivior
Mar 6, 2025
Maintains: Overweight
Price Target: $16 → $13
Current: $11.08
Upside: +17.33%
Viatris
Mar 5, 2025
Reiterates: Neutral
Price Target: $14 → $10
Current: $8.77
Upside: +14.03%
Feb 10, 2025
Maintains: Overweight
Price Target: $310 → $329
Current: $265.86
Upside: +23.75%
Jan 17, 2025
Maintains: Overweight
Price Target: $23 → $30
Current: $16.93
Upside: +77.20%
Jan 10, 2025
Maintains: Overweight
Price Target: $24 → $13
Current: $9.39
Upside: +38.45%
Jan 2, 2025
Maintains: Overweight
Price Target: $26 → $9
Current: $6.57
Upside: +36.99%
Nov 11, 2024
Maintains: Overweight
Price Target: $9 → $11
Current: $7.41
Upside: +48.45%
Oct 25, 2024
Reiterates: Overweight
Price Target: $38 → $37
Current: $30.13
Upside: +22.80%
Oct 11, 2024
Initiates: Overweight
Price Target: $68
Current: $66.30
Upside: +2.56%
Sep 11, 2024
Downgrades: Neutral
Price Target: $41 → $36
Current: $31.70
Upside: +13.56%
Aug 2, 2024
Downgrades: Underweight
Price Target: $9 → $3
Current: $4.59
Upside: -34.64%
Jul 3, 2024
Maintains: Overweight
Price Target: $42
Current: $25.12
Upside: +67.20%
Apr 29, 2024
Maintains: Overweight
Price Target: $22 → $24
Current: $8.71
Upside: +175.55%
Apr 11, 2024
Initiates: Overweight
Price Target: $10
Current: $2.79
Upside: +258.42%
Feb 16, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $0.71
Upside: +2,861.08%
Jan 16, 2024
Maintains: Overweight
Price Target: $90 → $113
Current: $107.76
Upside: +4.86%
Oct 16, 2023
Maintains: Overweight
Price Target: $72 → $42
Current: $34.06
Upside: +23.33%